explore -WSS

explore

author：hotspot 2025-09-29 20:10:24 - browse：56276

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Stanford president’s abrupt resignation sparks debate

WSS

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Delta passengers in Vegas fall sick while waiting on flight in triple

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Delta passengers in Vegas fall sick while waiting on flight in triple

Republican states more likely to report Covid vaccine side effects

hotspot

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Duchenne breakthrough therapy leaves behind pioneering families

The stock market has soared this year, but will it last? Experts weigh in

Hollywood unions extend contract negotiations for actors

Trial using CRISPR to edit HIV out of cells disappoints

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Mass General Brigham physicians react to latest merger step

How to save PrEP access — and even expand it

First Opinion on colorectal cancer screening: letter and response

knowledge

Medicare Advantage 2025 payments will dip, Biden administration says

Stanford president’s abrupt resignation sparks debate

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Hormonal contraceptives don’t actually treat endometriosis

Study: Black kids more likely to die after surgery than white kids

Oral obesity drug from Viking Therapeutics hits key early target

entertainment

Wikipedia

Wikipedia

focus